| 1. |
|
|
| 2. |
|
|
| 3. |
- Erlandsson, Ann, et al.
(författare)
-
In vivo clearing of idiotypic antibodies with antiidiotypic antibodies and their derivatives
- 2006
-
Ingår i: Molecular Immunology 2006;42:599-604.
-
Tidskriftsartikel (refereegranskat)abstract
- At immunolocalization of experimental tumors, idiotypic monoclonal antibodies, such as TS1 against cytokeratin 8, can be used to carry and deposit in vivo terapeutics in the tumor. These carriers also remain in the circulation and may cause negative side-effects in other tissues.In this report, several derivatives of the antiidiotypic antibody anti-TS1 were produced and tested for their clearing capacity of the idiotypic carrier antibody TS1. Intact monoclonal anri-TS1, scFv of a anti-TS1 and anti-TS1 Fab and Fab'2 fragments were produced by recombinant technology or by cleavage with Ficin. The scFv was tailored by use of the variable domain genes of the light and heavy chain from the hybridoma clone in combination with a (Gly4Ser)3-linker, followed by expression in E. coli. When tested for clearing capacity, the intact divalent antiidiotypic IgG was found to be the most efficient. The divalent Fab'2 and the monovalent Fab fragment also demonstrated significant clearing, but lower than the intact antiidiotypic IgG. The anti-TS1 scFv antibody when injected separately was not found to clear the idiotype, but could do so when preincubated with the idiotype. Rapid excretion and in vivo instability of this lowmolecular weight antibody fragment may be the major reasons. Similar results were obtained when the system was reversed and the 131I-labeled antiidiotype IgG was cleared with the idiotype Fab'2 fragment. It is concluded that both intact antiidiotypic IgG, Fab'2 and Fab fragments are able to clear the idiotypic antibodies. The experimental data support the conclusion that the Fc parts from both the idiotype and the antiidiotype may contribute to this elimination
|
|
| 4. |
- Mattsson, S., et al.
(författare)
-
Radiation Dose to Patients from from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances.
- 2015
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This report provides a compendium of current information relating to radiation dose to patients, including biokinetic models, biokinetic data, dose coefficients for organ and tissue absorbed doses, and effective dose for major radiopharmaceuticals based on the radiation protection guidance given in Publication 60 (ICRP, 1991). These data were mainly compiled from Publications 53 , 80, and 106 (ICRP, 1987, 1998, 2008), and related amendments and corrections. This report also includes new information for 82 Rb-chloride, iodide (123 I, 124 I, 125 I, and 131 I) and 123 Ilabelled 2.-carbomethoxy 3.-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FPCIT). The coefficients tabulated in this publication will be superseded in due course by values calculated using new International Commission on Radiation Units and Measurements/International Commission on Radiological Protection adult and paediatric reference phantoms and Publication 103 methodology (ICRP, 2007). The data presented in this report are intended for diagnostic nuclear medicine and not for therapeutic applications.
|
|
| 5. |
|
|
